Investor Relations
May 18, 2018
OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test MORE >>
May 08, 2018
OPKO Health Reports First Quarter 2018 Financial Results MORE >>
May 02, 2018
OPKO Health to Announce First Quarter 2018 Financial Results on May 8, 2018 MORE >>
May 01, 2018
OPKO Health Appoints Geoff Monk General Manager at BioReference Laboratories MORE >>

Press Releases

All Releases
OPKO To Announce First Quarter Financial Results on May 11, 2015
May 07, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) will announce first quarter 2015 financial results on Monday, May 11th , after the close of the U.S. financial markets. OPKO's senior management will host a conference call and live audio webcast to provide a business update and discuss its
CORRECTING and REPLACING OPKO To Announce First Quarter Financial Results on May 11, 2015
May 07, 2015
MIAMI --(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: OPKO TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS ON MAY 11, 2015 OPKO Health, Inc. (NYSE: OPK ) will announce first quarter 2015 financial results on
OPKO Health Acquires EirGen Pharma
May 05, 2015
Developer of High Potency Specialty Pharmaceutical Products Rich Pipeline of Products Products Currently on the Market in the U.S., Europe and Japan Adds Sophisticated Pharmaceutical Manufacturing Facilities in Ireland Co-Founded by Former IVAX Pharmaceuticals Executives MIAMI --(BUSINESS WIRE)--
OPKO Announces Publication of ProtecT Study Using Kallikrein Biomarkers in 4Kscore Test
Apr 21, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a study entitled " Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study " in the Journal of the National Cancer Institute .
Conversion Right Triggered on OPKO 3.0% Convertible Senior Notes
Apr 01, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that the Company's 3.0% Convertible Senior Notes due 2033 (the "Notes") are convertible by holders of such Notes. The Company has elected to satisfy its conversion obligation under the Notes in shares of the Company's Common
Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings
Mar 27, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), today announced the presentation of additional phase 3 clinical data in a poster at the National Kidney Foundation's Spring Clinical Meetings on March 27-28th, 2015 in Dallas, Texas , that will include data for 429 patients completing up to
OPKO Investee SciVac Ltd. Enters into Transaction with Levon Resources
Mar 23, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) announced today that SciVac Ltd. ("SciVac"), an Israeli entity in which OPKO has a forty-five percent ownership interest, has entered into an agreement pursuant to which Levon Resources Ltd. (LVN.TO)(OTC:LVNVF)(LO9.F) will acquire 100% of the
OPKO Lab Receives Accreditation From College of American Pathologists
Mar 18, 2015
CAP Accreditation is Awarded to Clinical Laboratories Meeting the Highest Standards of Excellence in Quality Laboratory Practices NASHVILLE, Tenn. & MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that the College of American Pathologists (CAP) has awarded accreditation to
Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference
Mar 06, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), today announced the presentation of late-breaking clinical data in a poster at the 97th Annual Meeting of the Endocrine Society (ENDO) on March 6th, 2015 in San Diego, California , that will include twelve months data from OPKO's phase 3
Twelve Months Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to Be Presented at ENDO 2015 Conference
Mar 03, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), today announced the presentation of two posters at the 97th Annual Meeting of the Endocrine Society (ENDO) on March 5 th , 2015 in San Diego, California , that will include twelve months data from OPKO's advanced phase 2 trial for its long
OPKO Announces Fourth Quarter Operating and Financial Results
Feb 27, 2015
Pfizer Collaboration Agreement for Long Acting Human Growth Hormone Closed in January 2015 ; OPKO Received $295 Million of $570 Million Total Potential Up Front and Milestone Payments Rayaldee TM New Drug Application (NDA) Submission Planned for Q1 2015 Positive Rayaldee Phase 3 Clinical Trial
OPKO to Announce Fourth Quarter and Full Year 2014 Financial Results on February 27, 2015
Feb 26, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) will announce fourth quarter and full year 2014 financial results on Friday, February 27 , after the close of the U.S. financial markets. OPKO's senior management will host a conference call and live audio webcast to provide a business update
OPKO Announces Publication of 20 Year Outcome Study for Lethal Prostate Cancer Using Kallikrein Biomarkers in 4Kscore Test
Feb 20, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a study entitled "Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study" in the journal
OPKO Health to Present at the 2015 RBC Capital Markets' Healthcare Conference
Feb 13, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the 2015 RBC Capital Markets' Healthcare Conference on Wednesday, February 25, 2015 at 2:35 PM (ET) . OPKO's senior management will provide a review of recent corporate developments.
OPKO Submits Investigational New Drug Application to Initiate a Phase 2a Trial for its Long-Acting Coagulation Factor VIIa-CTP to Treat Hemophilia
Jan 30, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health , Inc. (NYSE:OPK) announced the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to conduct a Phase 2a study of OPKO's long-acting version of coagulation Factor VIIa (Factor VIIa-CTP) for the treatment
OPKO and Pfizer Receive Regulatory Clearance for Global Agreement
Jan 29, 2015
MIAMI & NEW YORK --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) and Pfizer Inc. (NYSE: PFE) today announced the closing of their worldwide agreement for the development and commercialization of hGH-CTP, a long-acting human growth hormone. The closing follows termination of the waiting period
OPKO Launches the 4Kscore Test in Mexico
Jan 28, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the launch of the 4Kscore® test, the only blood test that accurately identifies risk for aggressive prostate cancer, in Mexico through its wholly owned subsidiary, OPKO Health Mexico. The launch in Mexico follows the U.S.
OPKO Claros1 Analyzer Selected for Development of a Rapid Lyme Disease Test Under Immuno Technologies NIH Grant
Jan 13, 2015
MIAMI & MEMPHIS, Tenn. --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) and Immuno Technologies, Inc. today announced that the National Institutes of Health (NIH) has awarded a $3 million grant to develop a rapid diagnostic test for Lyme disease. The Phase II Small Business Innovation Research
OPKO Health to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Jan 05, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that senior management will present at the 33 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 4:00 PM PT . A live audio webcast of the presentation will be accessible through the OPKO Investor
OPKO and Pfizer Enter into Global Agreement for OPKO's Long-Acting Human Growth Hormone (hGH-CTP)
Dec 15, 2014
  • hGH-CTP in global clinical development for the treatment of pediatric and adult growth hormone deficiency (GHD)
  • hGH-CTP has potential to reduce dosing frequency of human growth hormone to single weekly injection from current standard of daily injection
  • OPKO to receive upfront payment of $295 million and eligible to receive up to an additional $275 million upon achievement of regulatory milestones
  • Upon Pfizer's commercialization of hGH-CTP, OPKO is eligible to receive royalty and/or profit sharing payments
  • Pfizer to obtain exclusive license to commercialize hGH-CTP globally
Displaying 141 - 160 of 353